Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vanguard Plus 5
- Development stage
- Unknown
- Lead developer
- Zoetis
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
Vanguard Plus 5 is a multivalent veterinary vaccine developed by Zoetis (formerly Pfizer Animal Health) for the immunization of healthy dogs aged 6 weeks or older. It is a lyophilized (freeze-dried) preparation containing live attenuated strains of canine distemper (CD) virus, canine adenovirus type 2 (CAV-2), canine parainfluenza (CPI) virus, and canine parvovirus (CPV). The vaccine is specifically formulated with a high-titer, low-passage CPV strain designed to be highly immunogenic and capable of overcoming maternal antibody interference in young puppies. It provides protection against canine distemper, infectious canine hepatitis (caused by CAV-1), respiratory disease (caused by CAV-2), canine parainfluenza, and canine parvoviral enteritis (including disease caused by CPV-2c).
- Brand names
- Vanguard Plus 5
02
Targets
CAdV-2 (Canine adenovirus type 2)PIV5 (Parainfluenza virus 5)CPV capsid (Canine parvovirus capsid protein)
Beyond the preview
Go deeper on Vanguard Plus 5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vanguard Plus 5.